CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
We have now added a new section called the "Assay History List" to the "At A Gla...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...